Pathstone Family Office LLC held its stake in shares of Neurotrope Inc (OTCMKTS:NTRP) during the second quarter, according to its most recent disclosure with the SEC. The fund owned 30,646 shares of the company’s stock at the end of the second quarter. Pathstone Family Office LLC owned 0.39% of Neurotrope worth $287,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in NTRP. Bank of New York Mellon Corp purchased a new stake in Neurotrope during the 2nd quarter worth approximately $111,000. Spark Investment Management LLC purchased a new stake in Neurotrope during the 2nd quarter worth approximately $214,000. Cannell Peter B & Co. Inc. increased its stake in Neurotrope by 98.7% during the 2nd quarter. Cannell Peter B & Co. Inc. now owns 124,793 shares of the company’s stock worth $1,169,000 after buying an additional 62,000 shares in the last quarter. Finally, Oaktop Capital Management II L.P. purchased a new stake in Neurotrope during the 2nd quarter worth approximately $1,095,000.

WARNING: “Neurotrope Inc (NTRP) Stake Maintained by Pathstone Family Office LLC” was posted by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.dailypolitical.com/2017/09/21/neurotrope-inc-ntrp-stake-maintained-by-pathstone-family-office-llc.html.

Separately, ValuEngine upgraded Neurotrope from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st.

Neurotrope Inc (OTCMKTS:NTRP) opened at 5.65 on Thursday. The stock’s 50 day moving average price is $5.31 and its 200 day moving average price is $5.31. The firm’s market capitalization is $44.61 million. Neurotrope Inc has a one year low of $4.41 and a one year high of $20.83.

Neurotrope Company Profile

Neurotrope, Inc, formerly BlueFlash Communications, Inc, is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage.

Want to see what other hedge funds are holding NTRP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurotrope Inc (OTCMKTS:NTRP).

Institutional Ownership by Quarter for Neurotrope (OTCMKTS:NTRP)

Receive News & Ratings for Neurotrope Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope Inc and related companies with MarketBeat.com's FREE daily email newsletter.